ALGS

Aligos Therapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$1.98

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0.1 / %30

Non-compliant assets / Total market cap %48.6 / %30

Non-compliant revenue / Total income %9.6 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.

Website

Analysis (Turkish): ALGS Hissesi Caiz mi, Helal mi? Aligos Therapeutics, Inc. Katılım Analizi